Skip to main content

Table 2 Prescribing rates for CHD drugs

From: Practice characteristics and prescribing of cardiovascular drugs in areas with higher risk of CHD in Scotland: cross-sectional study

Drug

Star-PUs

 

Cases

Controls

Difference [95% C.I.]

% Difference

  

Unmatched

Matched

  

Statins* (BNF Chapter 2, 2.12)

98.9

99.4

136.7

-37.8 [-66.7 to -11.5]

-27.7%

Ace Inhibitors (BNF Chapter 2, 2.5.5)

104.7

97.3

144.4

-39.7 [-64.3 to -14.5]

-27.5%

Amlodipine BNF Chapter 2, 2.6)

89.2

107.0

102.2

-13.0 [-44.3 to 13.4]

-12.8%

Beta blockers (BNF Chapter 2, 2.4)

92.7

101.9

106.2

-13.5 [-38.9 to 9.9]

-12.7%

Clopidogrel (BNF Chapter 2, 2.9)

86.6

99.6

154.3

-67.6 [-105.8 to -17.8]

-43.9%

Thiazide ((BNF Chapter 2, 2.5)

92.7

103.4

134.8

-42.2 [-62.7 to -23.6]

-31.3%

Aspirin (BNF Chapter 2, 2.9)

109.0

102.2

136.2

-27.2 [-57.7 to 3.6]

-20%

Warfarin (BNF Chapter 2, 2.8)

77.2

100.2

101.7

-24.5 [-38.1 to -6.5]

-24.1%

Spironolactone (BNF Chapter 2, 2.5)

87.0

100.3

109.8

-22.9 [-63.9 to 0.6]

-20.8%

Digoxin (BNF Chapter 2, 2.1)

92.0

100.9

122.6

-30.6 [-55.7 to -9.6]

-25%

  1. Notes: * measured in Defined Daily Doses